Long-term Outcomes of Uveitis Associated with Vogt-Koyanagi-Harada Disease in the Pediatric Age Group

References

• Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi- Harada disease. J Immunol. 2000;165:7323–7329. doi:10.4049/jimmunol.165.12.7323.
   PubMed Web of Science ®Google Scholar
• Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res. 2000;71:361–369. doi:10.1006/exer.2000.0893.
   PubMed Web of Science ®Google Scholar
• Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2001;42:2004–2009.
   PubMed Web of Science ®Google Scholar
• Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res. 2008;33(7):517–523. doi:10.1080/02713680802233968.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:3. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:6. doi:10.1111/aos.12127.
   PubMedGoogle Scholar
• AlBloushi AF, Alfawaz AM, AlZaid A, Alsalamah AK, Gikandi PW, Abu El-Asrar AM. Incidence, risk factors and surgical outcomes of cataract among patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2019;27:1105–1113. doi:10.1080/09273948.2019.1668430. Published online.
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131(5):599–606.doi:10.1016/S0002-9394(01)00937-0.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265–292. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, Hemachandran S, Hariz R, Mousa A, Al-Muammar A. Chronic recurrent vogt-koyanagi-harada disease and development of ‘Sunset Glow Fundus’ predict worse retinal sensitivity. Ocul Immunol Inflamm. 2017;25(4):475–485. doi:10.3109/09273948.2016.1139730.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2017;95(1):85–90. doi:10.1111/aos.13189.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2012;90:8. doi:10.1111/j.1755-3768.2012.02498.x.
   Web of Science ®Google Scholar
• Rathinam SR, Vijayalaksmi P, Namperumasalmy P, Nozik RA, Cunninghman E. Research reports Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm. 1998;6(3):155–161. doi:10.1076/ocii.6.3.155.4041.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76(6):723–726. doi:10.1034/j.1600-0420.1998.760619.x.
   PubMedGoogle Scholar
• Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA. Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm. 2006;14(2):91–98. doi:10.1080/09273940600557001.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D. Vogt-Koyanagi-Harada disease in children. Eye. 2008;22(9):1124–1131. doi:10.1038/sj.eye.6702859.
   PubMed Web of Science ®Google Scholar
• Hamade IH, Al Shamsi HN, Al Dhibi H, Chacra CB, Ama E-A, Tabbara KF. Uveitis survey in children. Br J Ophthalmol. 2009;93(5):569–572. doi:10.1136/bjo.2008.148015.
   PubMed Web of Science ®Google Scholar
• Martin TD, Rathinam SR, Cunningham ET. Prevalence, clinical characteristics, and causes of vision loss in children with vogt-koyanagi-harada disease in south india. Retina. 2010;30(7):1113–1121. doi:10.1097/IAE.0b013e3181c96a87.
   PubMed Web of Science ®Google Scholar
• Marquezan MC, Nascimento H, Dalbem D, Muccioli C, Vogt-Koyanagi-Harada BR. Syndrome in Brazilian children. Ocul Immunol Inflamm. 2020;28(3):402–408. doi:10.1080/09273948.2019.1588982.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652.doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Finckh A, Liang MH, Van Herckenrode CM, De Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Care Res. 2006;55(6):864–872. doi:10.1002/art.22353.
   Web of Science ®Google Scholar
• Opdenakker G, Abu El-Asrar A, Van Damme J. Remnant epitopes generating autoimmunity: from model to useful paradigm. Trends Immunol. 2020;41(5):367–378. doi:10.1016/j.it.2020.03.004.
   PubMed Web of Science ®Google Scholar